IBN Coverage: Clene (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker With FDA Leadership

NewMediaWire10-26

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - (NewMediaWire) - October 25, 2024 - ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2478795598?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TRkRohp6.Y_6PckNhkFmhw--~B/aD04MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/newsmediawire_165/4e3818c66cba0f6e5d0ce979c9e8d382","is_english":true,"pubTime":"2024-10-26 00:09","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2478795598","market":"us","top_or_hot":-1,"title":"IBN Coverage: Clene (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker With FDA Leadership","media":"NewMediaWire","content":"<div>\n<p>This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community.\nLOS ANGELES, CA - (NewMediaWire) - October 25, 2024 - ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ibn-coverage-clene-nasdaq-clnn-160943072.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IBN Coverage: Clene (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker With FDA Leadership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIBN Coverage: Clene (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker With FDA Leadership\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-26 00:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ibn-coverage-clene-nasdaq-clnn-160943072.html><strong>NewMediaWire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community.\nLOS ANGELES, CA - (NewMediaWire) - October 25, 2024 - ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ibn-coverage-clene-nasdaq-clnn-160943072.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://finance.yahoo.com/news/ibn-coverage-clene-nasdaq-clnn-160943072.html","article_id":"2478795598","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TRkRohp6.Y_6PckNhkFmhw--~B/aD04MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/newsmediawire_165/4e3818c66cba0f6e5d0ce979c9e8d382"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2478795598","pubTimestamp":1729872583,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community.LOS ANGELES, CA -  - October 25, 2024 - Clene  and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis  and multiple sclerosis , recently announced an upcoming meeting with U.S. Food and Drug Administration  leadership. The focus is to discuss Clene's CNM-Au8 biomarker and related clinical and survival data for ALS. \"FDA's Director of the Office on New Drugs, the Director of the Office of Neuroscience, and the Division of Neurology 1  review team, as well as recognized key opinion leaders in ALS, biostatistics and biomarkers,\" will attend the meeting according to a recent article.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU0181495838.USD":"施罗德新兴亚洲A Acc","QLD":"纳指两倍做多ETF","PSQ":"纳指反向ETF","LU0828237940.HKD":"SCHRODER ISF EMERGING ASIA \"A\" (HKD) ACC","IE00B0JY6M65.USD":"PINEBRIDGE INDIA EQUITY \"A\" (USD) ACC","BK4207":"综合性银行","BK4022":"陆运","NDAQ":"纳斯达克OMX交易所","LU0066902890.USD":"HSBC GIF INDIAN EQUITY \"AD\" (USD) INC","LU0164881194.USD":"HSBC GIF INDIAN EQUITY \"AC\" (USD) ACC","WRD":"文远知行","IE00BYTNYM70.SGD":"PINEBRIDGE INDIA EQUITY \"A5\" (SGD) ACC","LU0823038988.USD":"AMUNDI FUNDS ASIA EQUITY FOCUS  \"A2\" (USD) ACC","CLNN":"Clene Inc","BK4232":"货物陆运","LU0264410563.USD":"SCHRODER ISF INDIAN EQUITY \"A\" ACC","TQQQ":"纳指三倍做多ETF","SQQQ":"纳指三倍做空ETF","CLNNW":"Clene Inc Warrant","LU0251143458.SGD":"Fidelity Emerging Markets A-SGD","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","BK4548":"巴美列捷福持仓","LU0823039010.USD":"AMUNDI FUNDS ASIA EQUITY FOCUS  \"A2\" (USD) INC","R":"瑞德系统","LU1102505762.USD":"富达新兴市场焦点 A","LU1868838027.USD":"CT (LUX) I GLOBAL EMERGING MARKET EQUITIES \"8\" (USD) ACC","LU1102505929.USD":"FIDELITY SUSTAINABLE EMERGING MARKETS EQUITY  \"A\" (USD) ACC","LU0143863784.USD":"CT (LUX) I GLOBAL EMERGING MARKET EQUITIES\"DU\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","DBP":"Invesco DB Precious Metals Fund","QID":"纳指两倍做空ETF","BK4523":"印度概念","BK4585":"ETF&股票定投概念","IE00B7N09G41.SGD":"柏瑞印度股票A5CP SGD",".IXIC":"NASDAQ Composite","IBN":"印度工业信贷投资银行","BK4139":"生物科技","LU1868837565.USD":"CT (LUX) I GLOBAL EMERGING MARKET EQUITIES \"1\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU1868837722.USD":"CT (LUX) I GLOBAL EMERGING MARKET EQUITIES \"2\" (USD) ACC","LU0143863198.USD":"CT (LUX) I GLOBAL EMERGING MARKET EQUITIES\"AU\" (USD) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4535":"淡马锡持仓","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"IBN报道：Clene（纳斯达克：CLNN）将与FDA领导层讨论主要候选生物标志物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WRD":1,"IBN":1,".IXIC":1,"R":1,"DBP":1,"NDAQ":1,"CLNN":1,"CLNNW":0.9,"PSQ":0.6,"QID":0.6,"QLD":0.6,"SQQQ":0.6,"TQQQ":0.6,"NQmain":0.6,"MNQmain":0.6},"content_text":"This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community.\nLOS ANGELES, CA - (NewMediaWire) - October 25, 2024 - Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (\"ALS\") and multiple sclerosis (\"MS\"), recently announced an upcoming meeting with U.S. Food and Drug Administration (\"FDA\") leadership. The focus is to discuss Clene's CNM-Au8(R) biomarker and related clinical and survival data for ALS. \"FDA's Director of the Office on New Drugs, the Director of the Office of Neuroscience, and the Division of Neurology 1 (DN1') review team, as well as recognized key opinion leaders in ALS, biostatistics and biomarkers,\" will attend the meeting according to a recent article.\n\"Clene looks forward to the opportunity to have experts present their views to the FDA and address questions on ALS biomarkers, related clinical endpoints and survival data, all of which Clene believes are essential for the understanding of its CNM-Au8,\" the company stated in a news release. Clene also voiced appreciation for the FDA's use of process and regulatory flexibility to obtain the best outcome for people living with ALS.\nTo view the full article, visit https://ibn.fm/3O2Zt\nAbout Clene Inc.\nClene (along with its subsidiaries, \"Clene\") and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease and multiple sclerosis. CNM-Au8(R) is an investigational first-in-class therapy that improves central nervous system cells' survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8(R) is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.\nForward-Looking Statements\nCertain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading \"Risk Factors\" discussed under the caption \"Item 1A. Risk Factors\" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption \"Item 1A. Risk Factors\" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.\nAbout IBN\nIBN is a cutting-edge communications and digital engagement platform providing tailored Platform Solutions for select private and public companies. Over the course of 18+ years, IBN has introduced over 65+ investor facing brands to the investment public and amassed a collective audience of millions of social media followers. These distinctive investor brands amplify recognition and reach as well as help fulfill the unique needs of our rapidly growing and diverse base of client-partners. IBN will continue to expand our branded network of influential properties as well as leverage the energy and experience of our team of professionals to best serve our clients.\nIBN's Platform Solutions provide access to: (1) our Dynamic Brand Portfolio (DBP) through 65+ investor facing brands; (2) article and editorial syndication to 5,000+ news outlets; (3) full-scale distribution to a growing social media audience; (4) a network of wire solutions via InvestorWire to effectively reach target markets and demographics; (5) Press Release Enhancement to ensure accuracy and impact; (6) a full array of corporate communications solutions; and (7) total news coverage solutions.\nFor more information, please visit https://www.InvestorBrandNetwork.com\nPlease see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer\nMedia Contact\nIBN (InvestorBrandNetwork)\nLos Angeles, California\nwww.InvestorBrandNetwork.com\n310.299.1717 Office\nEditor@InvestorBrandNetwork.com","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Policy And Regulatory","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2478795598"}